TNYA · Tenaya Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $14.84M | - | $15.36M | $17.37M | $21.08M | - | $20.35M | $22.65M | $25.05M | - |
| SG&A | $5.45M | - | $5.57M | $6.71M | $6.46M | - | $6.36M | $8.17M | $8.71M | - |
| Total Operating Expenses | $20.29M | - | $20.94M | $24.08M | $27.54M | - | $26.71M | $30.82M | $33.76M | - |
| D&A | $1.76M | - | $1.90M | $2.10M | $2.66M | - | $2.10M | $2.10M | $2.15M | - |
| Operating Income | ($20.07M) | - | ($20.94M) | ($24.08M) | ($27.54M) | - | ($26.71M) | ($30.82M) | ($33.76M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - | $0 | - |
| Net Income | ($19.27M) | - | ($20.27M) | ($23.28M) | ($26.86M) | - | ($25.63M) | ($29.43M) | ($32.23M) | - |
| EPS - Basic | ($0.09) | - | ($0.12) | ($0.14) | ($0.24) | - | ($0.30) | ($0.34) | ($0.40) | - |
| EPS - Diluted | ($0.09) | - | ($0.12) | ($0.14) | ($0.24) | - | ($0.30) | ($0.34) | ($0.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $80.89M | $100.55M | $56.31M | $62.67M | $53.77M | $4.32M | $8.23M | $58.13M | $59.30M | $45.68M |
| Accounts Receivable | $10.63M | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.91M | $3.58M | $2.84M | $3.30M | $5.06M | $5.16M | $5.84M | $4.32M | $6.66M | $5.63M |
| Current Assets | $96.56M | $105.59M | $61.24M | $75.88M | $94.48M | $67.38M | $85.33M | $105.03M | $128.70M | $111.58M |
| Total Assets | $135.07M | $146.92M | $104.98M | $122.15M | $143.95M | $119.94M | $140.58M | $163.19M | $184.90M | $170.51M |
| Current Liabilities | $16.78M | $15.44M | $13.21M | $12.65M | $14.15M | $15.97M | $16.18M | $16.71M | $19.16M | $22.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $28.88M | $23.66M | $22.11M | $22.32M | $24.56M | $27.09M | $27.98M | $29.19M | $26.72M | $31.09M |
| Stockholders' Equity | $106.19M | $123.27M | $82.87M | $99.83M | $119.40M | $92.85M | $112.60M | $134.00M | $158.18M | $139.42M |
| Retained Earnings | ($624.28M) | ($605.01M) | ($584.83M) | ($564.56M) | ($541.27M) | ($514.41M) | ($490.57M) | ($464.94M) | ($435.51M) | ($403.28M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($19.23M) | - | - | - | ($23.11M) | - | - | - | ($28.66M) | - |
| Investing Cash Flow | ($11.0K) | - | - | - | $22.30M | - | - | - | ($4.49M) | - |
| Financing Cash Flow | ($415.0K) | - | - | - | $50.26M | - | - | - | $46.77M | - |
| CapEx | $11.0K | - | - | - | $383.0K | - | - | - | $564.0K | - |
| Free Cash Flow | ($19.25M) | - | - | - | ($23.50M) | - | - | - | ($29.22M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.00 | - | - | - | 0.87 | - | - | - | 0.91 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.3% | - | -19.3% | -19.1% | -18.7% | - | -18.2% | -18.0% | -17.4% | - |
| Return on equity | -18.1% | - | -24.5% | -23.3% | -22.5% | - | -22.8% | -22.0% | -20.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.75 | 6.84 | 4.64 | 6.00 | 6.68 | 4.22 | 5.27 | 6.28 | 6.72 | 4.91 |
| Quick ratio | 5.75 | 6.84 | 4.64 | 6.00 | 6.68 | 4.22 | 5.27 | 6.28 | 6.72 | 4.91 |
| Cash ratio | 4.82 | 6.51 | 4.26 | 4.95 | 3.80 | 0.27 | 0.51 | 3.48 | 3.10 | 2.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.27 | 1.19 | 1.27 | 1.22 | 1.21 | 1.29 | 1.25 | 1.22 | 1.17 | 1.22 |
| Liabilities / Assets | 0.21 | 0.16 | 0.21 | 0.18 | 0.17 | 0.23 | 0.20 | 0.18 | 0.14 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.4x | - | 3.2x | 1.0x | 0.5x | - | 1.5x | 2.0x | 2.7x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 27.1% | - | 21.6% | 21.9% | 18.4% | - | 13.6% | 12.2% | -0.1% | - |
| Net income growth (YoY) | 28.3% | - | 20.9% | 20.9% | 16.6% | - | 12.0% | 11.5% | -1.5% | - |
| EPS growth (YoY) | 62.5% | - | 60.0% | 58.8% | 40.0% | - | 23.1% | 50.7% | 7.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 18.1% | - | - | - | 19.6% | - | - | - | 5.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -11.1% | 32.8% | -26.4% | -25.5% | -24.5% | -33.4% | -31.7% | -29.5% | -26.6% | -42.7% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Tenaya Therapeutics against the 5 most active filers in the same SIC group.